CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue
Total operating revenue	$ 252,483,000	$ 203,003,000
Operating expenses
Goodwill impairment charges	9,944,000	0
Selling, general and administrative expense	119,689,000	83,365,000
Depreciation and amortization	4,411,000	3,341,000
Total operating expenses	334,434,000	248,861,000
Loss from operations	(81,951,000)	(45,858,000)
Other non-operating expense (income)
Interest expense, net	4,082,000	320,000
Change in fair value of derivative warrant liabilities	(1,843,000)	(3,686,000)
Change in fair value of earnout liabilities	(59,215,000)	(24,891,000)
Change in fair value of conversion option derivative liabilities	(24,200,000)	0
Gain on loan forgiveness	(183,000)	(4,957,000)
Other, net	(501,000)	(1,046,000)
Total other non-operating income	(81,860,000)	(34,260,000)
Loss before provision for income taxes	(91,000)	(11,598,000)
Income tax benefit	243,000	671,000
Net income (loss)	152,000	(10,927,000)
Net income (loss) per share attributable to common stockholders:
Net income (loss) attributable to common stockholders, basic	$ 68,000	$ (10,628,000)
Weighted-average number of shares outstanding, basic (in shares)	72,793,497	66,230,606
Net income (loss) per share attributable to common stockholders, basic (in usd per share)	$ 0	$ (0.16)
Net loss attributable to common stockholders, diluted	$ (16,980,000)	$ (10,628,000)
Weighted-average number of shares outstanding, diluted (in shares)	80,605,600	66,230,606
Net loss per share attributable to common stockholders, diluted (in usd per share)	$ (0.21)	$ (0.16)
Patient services
Revenue
Total operating revenue	$ 166,785,000	$ 124,074,000
Operating expenses
Direct costs	134,761,000	99,401,000
Dispensary
Revenue
Total operating revenue	79,343,000	72,550,000
Operating expenses
Direct costs	65,111,000	62,102,000
Clinical trials & other
Revenue
Total operating revenue	6,355,000	6,379,000
Operating expenses
Direct costs	$ 518,000	$ 652,000